HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies

MLA

van Tilborg, Marjolein, et al. “HCV Core Antigen as an Alternative to HCV RNA Testing in the Era of Direct-Acting Antivirals: Retrospective Screening and Diagnostic Cohort Studies.” The Lancet Gastroenterology & Hepatology, vol. 3, no. 12, Dec. 2018, pp. 856–64. EBSCOhost, https://doi.org/10.1016/S2468-1253(18)30271-1.

APA

van Tilborg, M., Al Marzooqi, S. H., Wong, W. W. L., Maan, R., Vermehren, J., Maasoumy, B., Mazzulli, T., Bolotin, S., Garber, G., Guerra, F., Flud, C. R., Kowgier, M., Janssen, H. L., de Knegt, R. J., Pawlotsky, J.-M., Cloherty, G. A., Duarte-Rojo, A., Sarrazin, C., Wedemeyer, H., & Feld, J. J. (2018). HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies. The Lancet Gastroenterology & Hepatology, 3(12), 856–864. https://doi.org/10.1016/S2468-1253(18)30271-1

Chicago

van Tilborg, Marjolein, Saeed H Al Marzooqi, William W L Wong, Raoel Maan, Johannes Vermehren, Benjamin Maasoumy, Tony Mazzulli, et al. 2018. “HCV Core Antigen as an Alternative to HCV RNA Testing in the Era of Direct-Acting Antivirals: Retrospective Screening and Diagnostic Cohort Studies.” The Lancet Gastroenterology & Hepatology 3 (12): 856–64. doi:10.1016/S2468-1253(18)30271-1.